AR081975A1 - Analogos de glucagon - Google Patents

Analogos de glucagon

Info

Publication number
AR081975A1
AR081975A1 ARP110102166A ARP110102166A AR081975A1 AR 081975 A1 AR081975 A1 AR 081975A1 AR P110102166 A ARP110102166 A AR P110102166A AR P110102166 A ARP110102166 A AR P110102166A AR 081975 A1 AR081975 A1 AR 081975A1
Authority
AR
Argentina
Prior art keywords
ser
leu
lys
tyr
glu
Prior art date
Application number
ARP110102166A
Other languages
English (en)
Inventor
Eddi Meier
Jens Rosengren Daugaard
Marie Skovgaard
Riber Ditte
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081975(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of AR081975A1 publication Critical patent/AR081975A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente proporciona materiales y procedimientos para promover la pérdida de peso o prevenir el aumento de peso sin afectar al control de la glucemia. En particular, se proporciona péptidos análogos de glucagón eficaces en tales procedimientos. Los péptidos pueden mediar su efecto teniendo selectividad aumentada para el receptor de GLP-1 en comparación con el glucagón humano.Reivindicación 1: Un compuesto que tiene la fórmula: R1-X-Z-R2 en la que R1 es H, alquilo C1-4, acetilo, formilo, benzoilo o trifluoroacetilo; R2 es OH o NH2; X es un péptido que tiene la fórmula: His-X2-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-X16-X17-Arg-Ala-X20-Asp-Phe-Ile-Glu-Trp-Leu-X27-X28-X29 en la que X2 se selecciona de Ser y Aib; X16 se selecciona de Glu e Y; X17 se selecciona de Arg e Y; X20 se selecciona de Lys e Y; X27 se selecciona de Leu e Y; X28 se selecciona de Ser e Y o está ausente; X29 es Ala o está ausente; en la que al menos uno de X16, X17, X20, X27 y X28 es Y; en la que cada resto Y se selecciona independientemente de Lys, Cys y Orn; en la que la cadena lateral de al menos un resto de aminoácido Y de X está conjugada con un sustituyente lipófilo que tiene la fórmula: (i) Z1, en la que Z1 es un resto lipófilo conjugado directamente con la cadena lateral de Y; o (ii) Z1Z2, en la que Z1 es un resto lipófilo, Z2 es un espaciador y Z1 está conjugado con la cadena lateral de Y por medio de Z2; y Z está ausente o es una secuencia de 1 - 20 unidades de aminoácidos seleccionados del grupo constituido por Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr y Orn; o una sal farmacéuticamente aceptable del mismo.
ARP110102166A 2010-06-23 2011-06-22 Analogos de glucagon AR081975A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201000550 2010-06-23
US35862310P 2010-06-25 2010-06-25

Publications (1)

Publication Number Publication Date
AR081975A1 true AR081975A1 (es) 2012-10-31

Family

ID=44630045

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102166A AR081975A1 (es) 2010-06-23 2011-06-22 Analogos de glucagon

Country Status (22)

Country Link
US (2) US9403894B2 (es)
EP (1) EP2585481B1 (es)
JP (1) JP5937582B2 (es)
KR (1) KR20130086339A (es)
CN (1) CN103038250A (es)
AP (1) AP3286A (es)
AR (1) AR081975A1 (es)
AU (1) AU2011269427A1 (es)
BR (1) BR112012033227A2 (es)
CA (1) CA2802889A1 (es)
CL (1) CL2012003643A1 (es)
CO (1) CO6660484A2 (es)
EA (1) EA201291233A1 (es)
EC (1) ECSP12012351A (es)
MX (1) MX2012014774A (es)
NZ (1) NZ604033A (es)
PE (1) PE20130326A1 (es)
SG (1) SG186276A1 (es)
TN (1) TN2012000567A1 (es)
TW (1) TW201202265A (es)
UY (1) UY33462A (es)
WO (1) WO2011160630A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013431A (es) 2005-05-04 2008-01-18 Zealand Pharma As Analogos del peptido 2 semejante al glucagon.
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
BRPI0823376A2 (pt) 2008-12-15 2015-06-16 Zealand Pharma As Análagos de glucagon
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
SG186764A1 (en) 2010-06-24 2013-02-28 Zealand Pharma As Glucagon analogues
AR085086A1 (es) * 2011-01-20 2013-09-11 Zealand Pharma As Uso de analogos de glucagon acilados
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
CN104144696A (zh) * 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
BR112014027348B1 (pt) 2012-05-03 2022-12-20 Zealand Pharma A/S Compostos agonistas duplos gip-glp-1 e métodos
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
EA201590011A1 (ru) 2012-06-14 2015-05-29 Санофи Пептидные аналоги эксендина-4
US10442847B2 (en) 2012-07-23 2019-10-15 Zealand Pharma A/S Glucagon analogues
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
GB2505941A (en) * 2012-09-17 2014-03-19 Imp Innovations Ltd Peptide analogues of glucagon for the treatment of obesity and diabetes
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
CN105189465B (zh) 2013-03-21 2019-02-26 赛诺菲-安万特德国有限公司 合成含有乙内酰脲的肽产物
US10450343B2 (en) 2013-03-21 2019-10-22 Sanofi-Aventis Deutschland Gmbh Synthesis of cyclic imide containing peptide products
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112016008115B1 (pt) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
BR112016009889B1 (pt) 2013-11-06 2023-11-28 Zealand Pharma A/S Análogo do gip, composição farmacêutica compreendendo um análogo do gip, ou um sal farmaceuticamente aceitável do mesmo, e seu uso
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
DK3258919T4 (da) 2015-02-17 2022-11-21 Lilly Co Eli Næsepulverformulering til behandling af hypoglykæmi
CN107567459B (zh) 2015-03-18 2021-09-24 西兰制药公司 胰淀素类似物
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3888667B1 (en) 2016-06-09 2023-10-25 AmideBio LLC Glucagon analog and methods of use thereof
MA45843B1 (fr) 2016-08-05 2021-06-30 Boehringer Ingelheim Int Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
CA3073011C (en) * 2017-08-16 2023-06-13 Dong-A St Co., Ltd. Acylated oxyntomodulin peptide analog
JP7015396B2 (ja) 2018-02-02 2022-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤としての、ベンジル－、（ピリジン－３－イル）メチル－または（ピリジン－４－イル）メチル置換オキサジアゾロピリジン誘導体
JP7225253B2 (ja) 2018-02-02 2023-02-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのピラゾール置換及びインダゾール置換オキサジアゾロピリジン誘導体
CN111683951B (zh) 2018-02-02 2023-10-13 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的三唑并嘧啶衍生物
CA3087827A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CA3096493A1 (en) * 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
CA3096495A1 (en) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Lixisenatide synthesis with capping
WO2020125744A1 (zh) 2018-12-21 2020-06-25 江苏恒瑞医药股份有限公司 双特异性蛋白
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
CA3156452A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh NPY2 RECEPTOR AGONISTS
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法
CN113278060B (zh) * 2020-05-29 2022-03-25 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
CA2265900C (en) 1996-09-09 2007-07-31 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
AU724326B2 (en) 1996-09-09 2000-09-14 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
NZ511931A (en) 1998-12-07 2004-01-30 Sod Conseils Rech Applic Analogues of glucagon like peptide-1
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
ES2315226T3 (es) 1999-03-17 2009-04-01 Novo Nordisk A/S Metodo de acilacion de peptidos y proteinas.
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
WO2003053339A2 (en) 2001-12-20 2003-07-03 Eli Lilly And Company Insulin molecule having protracted time action
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
AU2004234345A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
BRPI0612069A2 (pt) 2005-06-13 2009-01-20 Imp Innovations Ltd compostos e seus efeitos sobre o comportamento de alimentaÇço
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
CN101622276B (zh) 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
DK2217265T3 (en) 2007-11-20 2017-07-03 Ambrx Inc Modified insulin polypeptides and their use
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2711752A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
WO2009129250A2 (en) 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
AU2009240636A1 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN104447980A (zh) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
MX2010013454A (es) 2008-06-17 2011-01-21 Tion Indiana University Res And Technology Corpora Co-agonistas de receptor de glucagon/glp-1.
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
KR20110061552A (ko) 2008-07-31 2011-06-09 케이스 웨스턴 리저브 유니버시티 할로겐 안정화된 인슐린
BRPI0823376A2 (pt) 2008-12-15 2015-06-16 Zealand Pharma As Análagos de glucagon
EA020596B1 (ru) * 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
AU2008365555B2 (en) * 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
JP2013517307A (ja) * 2010-01-20 2013-05-16 ジーランド ファーマ アクティーゼルスカブ 心臓病の処置
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
SG186764A1 (en) 2010-06-24 2013-02-28 Zealand Pharma As Glucagon analogues
AR085086A1 (es) 2011-01-20 2013-09-11 Zealand Pharma As Uso de analogos de glucagon acilados
CN104144696A (zh) 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016008115B1 (pt) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh Análogos de glucagon acilados

Also Published As

Publication number Publication date
US20130157935A1 (en) 2013-06-20
JP2013534919A (ja) 2013-09-09
CN103038250A (zh) 2013-04-10
KR20130086339A (ko) 2013-08-01
EP2585481A2 (en) 2013-05-01
ECSP12012351A (es) 2013-01-31
SG186276A1 (en) 2013-01-30
PE20130326A1 (es) 2013-03-17
UY33462A (es) 2012-01-31
CL2012003643A1 (es) 2013-08-02
AP3286A (en) 2015-05-31
TN2012000567A1 (en) 2014-04-01
MX2012014774A (es) 2013-01-29
AP2013006669A0 (en) 2013-01-31
US20160304576A1 (en) 2016-10-20
CO6660484A2 (es) 2013-04-30
US9403894B2 (en) 2016-08-02
EA201291233A1 (ru) 2013-07-30
BR112012033227A2 (pt) 2017-06-20
WO2011160630A3 (en) 2012-02-16
JP5937582B2 (ja) 2016-06-22
TW201202265A (en) 2012-01-16
WO2011160630A2 (en) 2011-12-29
EP2585481B1 (en) 2015-08-19
AU2011269427A1 (en) 2012-12-20
CA2802889A1 (en) 2011-12-29
NZ604033A (en) 2014-12-24

Similar Documents

Publication Publication Date Title
AR081975A1 (es) Analogos de glucagon
AR088161A1 (es) Analogos de glucagon
PE20142113A1 (es) Analogos de glucagon
NZ597981A (en) Acylated glucagon analogues
PE20160683A1 (es) Analogos de glucagon acilados
AU2007319066B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
AR094178A1 (es) Derivados de exendina-4 funcionalizada
ES2647418T3 (es) Derivados de exendina-4 como agonistas dobles de GLP1/glucagón
ES2762580T3 (es) Inhibidores macrocíclicos de las interacciones proteína/proteína PD-1/PD-L1 y CD80(B7-1)/PD-L1
AR091866A1 (es) Analogos del glucagon
ES2406090T3 (es) Péptidos que tienen actividad farmacológica para tratar los trastornos asociados con la alteración de la migración celular, tal como el cáncer
AR085086A1 (es) Uso de analogos de glucagon acilados
RU2013154047A (ru) Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности
AR104932A1 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
PE20130338A1 (es) Analogos del glucagon
RU2014101697A (ru) Коагонисты рецепторов глюкагона/glp-1
MX2015016875A (es) Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.
PE20110435A1 (es) Composiciones antagonistas del pd-1
CA2742528A1 (en) Apj receptor compounds
BR112012014475A2 (pt) derivados de glp-acilados.
MX2015016564A (es) Derivados de peptido similar al glucaton tipo 1 (glp-1) y uso de los mismos.
AR065349A1 (es) Coagonistas del receptor de glucagon/glp-1
CL2009001425A1 (es) Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
KR20110017874A (ko) 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제
PE20200678A1 (es) Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2)

Legal Events

Date Code Title Description
FB Suspension of granting procedure